Intracerebral delivery of hCNTF has shown considerable neuroprotective potential in animal models of Huntington's disease (HD). The present study describes the relationship between a range of hCNTF doses and the resulting behavioral and neurochemical (striatal ChAT and GAD activity) protection in a rodent model of HD. Encapsulated BHK delivering a range of hCNTF doses were implanted into the lateral ventricle ipsilateral to an intrastriatal quinolinic acid (QA) injection. Results demonstrated a dose-dependent effect of hCNTF with complete, partial, and no observable neuroprotection occurring with preimplant doses of hCNTF of 30.8, 8.6, and 0.8-2.1 ng hCNTF/24 h, respectively. These data continue to support the use of cellular delivery of hCNTF for HD and will facilitate the optimization of this approach in the clinical situation.
INTRODUCTION
sis of HD early in life, even in utero (24). The ability to identify presymptomatic individuals provides the opportunity to design interventions that could intercede far be-Huntington's disease (HD) is a devastating autosomal dominant neurodegenerative disorder that usually begins fore the development of substantial neurodegeneration and the expression of the behavioral changes. Accord-in midlife and is characterized by an intractable course of mental deterioration and progressive motor abnormal-ingly, the preservation of the neuronal cytoarchitecture and physiology of the striatum could be maintained, ities that invariably results in death. There are no effective treatments (19) . Although medications may reduce while forestalling the debilitating consequences of the disease. Recent studies have demonstrated that intracere-the severity of chorea or diminish the behavioral symptoms, they do not increase patient survival or substan-bral delivery of CNTF preserves multiple populations of striatal neurons, including GABAergic neurons in both tially improve quality of life (23) . Pathogenetically, HD is characterized by a programmed, premature death of rodents and nonhuman primates (3,5-7, 17, 18, 20) . Based on these encouraging results, initial clinical tri-specific populations of neurons. The genetic defect on chromosome 4 results in an increase in the number of als are under way in which HD patients have received intraventricular implants of polymer encapsulated CNTF-polyglutamine-encoding CAG repeats at a site encoding for the protein huntingtin. The expanded CAG repeats producing cells (1). Although the case for clinical evaluation is compelling, several basic issues remain unre-produces a "gain of function" that mediates the clinical and pathological sequelae of HD, although the mecha-solved. One issue is to determine the dose of CNTF that must be delivered to the site of degeneration (i.e., the nism by which this occurs remains unknown. Unlike many other neurodegenerative diseases, the polygluta-striatum) to produce any neuroprotective effects. To date all studies delivering CNTF to the striatum in animal mine expression in HD permits an unequivocal diagno-840 EMERICH models of HD have delivered only a single dose. Al-Taconic Farms, Germantown, NY) approximately 2 months old and weighing 225-250 g were housed in though Regulier and colleagues (20) reported a dosedependent neuroprotective effect of CNTF delivered pairs in polypropylene cages with free access to food and water. The vivarium was maintained on a 12-h light/ using a tetracycline regulated lentiviral vector, these studies simply reported the levels of CNTF within stria-12-h dark cycle (lights on at 0700) with a room temperature of 22 ± 1°C and relative humidity level of 50 ± 5%. tal tissue after delivery of a single concentration of the viral vector in either its on or off state. To further build upon these findings, the following studies systematically Surgery evaluated the neurochemical and behavioral effects of a Prior to surgery, rats were anesthetized with sodium range of doses of CNTF delivered from polymer-encappentobarbital (45 mg/kg, IP) and positioned in a stereosulated cells into the quinolinic acid (QA)-lesioned striataxic instrument (Kopf, Tujunga, CA). A midline incitum. In this manner, greater insight will be achieved resion was made in the scalp and a hole drilled through garding the dose of CNTF required for full and partial the skull for placement of a cell-loaded capsule into neuroprotection.
the lateral ventricle using an 18-gauge Teflon catheter mounted to the stereotaxic frame. The stereotaxic co-MATERIALS AND METHODS ordinates for implantation were: 0.5 mm anterior to BHK-hCNTF Cell Line Production bregma, 1.5 mm lateral to the sagittal suture, and 7.5. The pNUT-hCNTF-TK construct was introduced into mm below the cortical surface. Following implantation, BHK cells using a standard calcium phosphate-mediated the skin was sutured closed. transfection method as previously reported (5). BHK One week following implantation of the polymer decells were grown in DMEM containing 10% fetal bovine vices, all animals were anesthetized, placed into the steserum and 2 mM L-glutamine (Gibco) in 5% CO 2 and at reotaxic instrument, and unilaterally injected with 225 37°C. Transfected cells were selected in medium connmol of QA (Sigma) into the striatum at the following taining 200 µM methotrexate (Sigma) for 3-4 weeks coordinates: 1.2 mm anterior to bregma, 2.6. mm lateral and resistant cells were maintained as a polyclonal popto the sagittal suture, and 5.5 mm ventral to the surface ulation either with or without 200 µM methotrexate.
of the brain. QA was infused using a 28-gauge Hamilton Mock-transfected cells served as controls.
syringe in a volume of 1 µl over 5 min. The injection cannula was left in place for an additional 2 min to allow Encapsulation Procedure the QA to diffuse from the needle tip, after which the Hollow fibers of poly (acrylonitrile-co-vinyl chloride, cannula was removed and the skin sutured closed. Con-PAN-PVC) copolymer were fabricated by a dry-wet trol animals received either no capsule or capsules con-(jet) spinning technique. As previously described (5), taining mock-transfected cells. Based on preimplant BHK cells with or without hCNTF were removed from hCNTF levels, the cell-loaded devices were individually culture flasks using Ca 2+ and Mg 2+ -free HBSS and trysin/ selected and placed into one of the following dosage EDTA and prepared as a single-cell suspension. The groups: 1) QA lesion, no capsule (n = 8); 2) QA lesion BHK cell suspensions were mixed with collagen to pro-+ control cells (n = 8); 3) QA lesion + CNTF dose A = vide densities of 20 million cells/ml, 5 million cells/ml, 30-32 ng/ml (n = 8); 4) QA lesion + CNTF dose B = 1.25 million cells/ml, and 300 thousand cells/ml and 8-10 ng/ml (n = 8); 5) QA lesion + CNTF dose C = 2-3 were loaded into the encapsulation devices as previously ng/ml (n = 8); 6) QA lesion + CNTF dose D = 0.5-0.9 described (5). After infusion of the cellular suspension, ng/ml (n = 8). the final assembled device had an outer diameter of ap-Immediately following the QA lesion, animals were proximately 750 µM with a length of 7 mm. All cellinjected IP with 10 ml of a lactated Ringer's solution. loaded devices were maintained in serum-free medium Twenty-eight days post-capsule implantation (21 days 2-3 days prior to hCNTF analysis by ELISA (5). For post-QA), animals were anesthetized and decapitated. the ELISA, the cell-loaded capsules were rinsed in The previously implanted devices were retrieved for HBSS, placed in 1 ml of fresh PC-1 medium, and the hCNTF analysis and the striata rapidly dissected on ice conditioned medium was collected and assayed at 24 h. and frozen at −80°C.
Animals
Striatal Neurochemistry All experimental procedures were reviewed and approved by the Institutional Animal Care and Use Com-
The left and right striata from each animal were processed for glutamic acid decarboxylase (GAD) and cho-mittee and the study was conducted in compliance with the American Association for Accreditation of Labora-line acetyltransferase (ChAT) activity using previously published protocols (6). tory Animal Care. Male Sprague-Dawley rats (N = 48; lowed to move on its own. The number of steps taken †p < 0.05 versus intact striatum.
with the forelimb the rat was standing on was recorded ‡p < 0.05 versus no capsule group.
during the 30-s trial for each forelimb. Rats were given one trial 14 days postlesion. atum relative to the contralateral intact striatum. This RESULTS effect was comparable in magnitude in animals that re-hCNTF ELISA ceived QA lesions plus no capsule and those receiving devices loaded with control BHK cells implanted into Prior to implantation and following retrieval the enthe adjacent ventricle. hCNTF produced a clear dosecapsulated BHK cells were incubated in conditioned medependent neuroprotection. In fact, there was no statisdium and assayed for hCNTF by ELISA. The preimplant tically significant effect of the QA lesion on striatal and postexplant hCNTF levels are shown in Table 1 . All ChAT or GAD levels in animals that were previously cell-loaded devices contained detectable hCNTF prior to implanted with BHK-hCNTF cells delivering the highest and following implantation while hCNTF was never dedose (30.8 ± 5.7 ng/24 h) of hCNTF. Lowering the dose tected in control devices. of hCNTF to 8.6 ± 1.7 ng/24 h partially but significantly Neurochemistry protected against the loss of ChAT and GAD activity while implantation of similar devices delivering lower The ChAT and GAD levels were analyzed separately levels of hCNTF (0.8-2.1 ng/24 h) failed to exert any in the lesioned versus intact striatum. As shown in Table  demonstrable effect on these neurochemical measures 2, the QA lesion produced a significant ( p < 0.01) loss following QA. The loss of ChAT and GAD in these aniof both ChAT and GAD activity within the lesioned strimals did not differ from animal receiving either no capsule or capsules containing BHK control cells. dependent behavioral protection was observed when demonstrating that behavioral and anatomical protection occurs when the levels of hCNTF within the striatum encapsulated CNTF-producing cells were implanted into the lateral ventricle immediately adjacent to the QA-are at a certain level (i.e., approx. 15 ng CNTF/mg tissue), they failed to provide a true dose-response curve lesioned striatum. Animals receiving the highest dose of hCNTF exhibited minor deficits on three behavioral by determining both maximally and minimally effective doses. The present studies demonstrate that by simply tasks, but these trends did not reach statistical significance. Also, in agreement with the observed neurochem-altering the numbers of hCNTF-producing BHK cells in polymer devices a wide range of doses of hCNTF can ical protection, the intermediate dose of hCNTF produced a significant partial behavioral protection while be effectively delivered to the striatum. Preimplant delivery of 30.8 ng of hCNTF/24 h produced virtually the two lower doses did not impact performance on these tasks relative to control animals.
complete neuroprotection in this model while approximately one quarter of that dose (8.6 ng/24 h) produced DISCUSSION only partial recovery. In contrast, lower doses (0.8-2.1 ng/24 h) were ineffective. These data clearly suggest The present series of experiments confirms previous results demonstrating that local delivery of hCNTF can that the dose of the hCNTF delivery to the target site is a critical variable in using this approach or likely cell-prevent the anatomical and neurobehavioral sequelae seen in an animal model of HD (3,5-7, 17, 18, 20) . QA based approach, to prevent the neurodegeneration associated with HD. produced a pronounced loss of striatal ChAT and GAD activity together with significant deficits in performance If trophic factors prove to be a worthwhile therapeutic strategy, the method of delivery may be critical. To on a series of motor tests. Implantation of encapsulated CNTF-producing cells into the adjacent lateral ventricle date, long-term administration of growth factors has been limited to intraventricular infusions using cannulae prevented the loss of ChAT and GAD activity and also obviated the deficits in behavioral performance. These or pumps. These routes of administration require repeated injections or refilling of pump reservoirs to main-studies extend previous data and clearly indicate that the ability of hCNTF to exert neuroprotective effects in this tain specific drug levels and avoid the degradation of the therapeutic agent in solution. Additionally, chronic model is intimately tied to the dose of hCNTF delivered to the lesion site. Previous studies in rodents have pro-low-dose infusion of compounds is difficult to sustain using current pump technology. Current pump technol-vided some evidence of the dose of hCNTF needed to effectively exert a neuroprotective effect (20) . While ogy is also suitable for ventricular but not parenchymal
